---
layout: default
title: Degarelix
parent: 僅模型預測 (L5)
nav_order: 117
evidence_level: L5
indication_count: 10
---

# Degarelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Degarelix: From Advanced Prostate Cancer to Hypertrichosis

## One-Sentence Summary

> Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist generally used in advanced, hormone-dependent prostate cancer.
> The TxGNN model predicts it may be effective for **Hypertrichosis (disease)**,
> but this ranks as the top of a broader list of low-plausibility predictions, with **0 clinical trials** and **0 publications** currently supporting this specific indication.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Advanced hormone-dependent prostate cancer (based on general drug class knowledge; not present in this evidence pack — see Data Gaps) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on general known information, Degarelix is a GnRH receptor antagonist that suppresses luteinizing hormone and testosterone release, an effect well established in advanced prostate cancer.

The top-ranked predicted indication, hypertrichosis, is mechanistically linked only in a narrow subset of cases: some androgen-dependent hypertrichosis subtypes could theoretically respond to testosterone suppression. However, the majority of hypertrichosis presentations (including the congenital and hair-shaft-structural subtypes also predicted at lower ranks) are not androgen-driven and have no known relationship to the HPG axis.

No clinical trials, ICTRP registrations, or PubMed literature specific to degarelix and hypertrichosis were found. Notably, the 20 literature records retrieved under rank 4 ("malformation syndrome with odontal/periodontal component") were reviewed and found to concern periodontitis pathology and treatment generally — they do not mention degarelix or GnRH antagonists and appear to be a keyword-matching artifact rather than genuine supporting evidence. This prediction should be treated as a model-score-only hypothesis (L5) pending mechanistic and clinical validation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Finland Market Information

Degarelix is currently **not marketed** in Finland (0 marketing authorizations found in the queried registry).

---

## Safety Considerations

Please refer to the package insert for safety information.

*Note: TFDA/Fimea package insert warnings and contraindications data could not be retrieved (Blocking data gap DG001) and are required before any S1 safety pre-assessment can proceed.*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by TxGNN model score with no corroborating clinical trials or literature (Evidence Level L5), and the mechanistic rationale applies to only a narrow, androgen-dependent subset of hypertrichosis. A Blocking-severity gap in regulatory safety data (TFDA/Fimea package insert) also prevents any safety pre-assessment.

**To proceed, the following is needed:**
- TFDA/Fimea package insert (warnings, contraindications) — Blocking gap DG001
- Confirmed mechanism of action data from DrugBank — High-priority gap DG002
- Targeted literature/clinical search specifically for "degarelix AND hypertrichosis" (current 20-record literature match under rank 4 is unrelated noise and should be excluded)
- Preclinical or case-level evidence establishing a causal link between androgen suppression and the specific hypertrichosis subtype targeted
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

